Which medications in the drug class Antineoplastics, Tyrosine Kinase Inhibitor are used in the treatment of Hepatocellular Carcinoma (HCC)?

Updated: Jan 31, 2021
  • Author: Luca Cicalese, MD, FACS; Chief Editor: John Geibel, MD, MSc, DSc, AGAF  more...
  • Print

Antineoplastics, Tyrosine Kinase Inhibitor

Tyrosine kinase inhibitors have shown inhibitory activity of membrane-bound and intracellular kinases involved in normal cellular functions and in pathological processes.

Sorafenib (Nexavar)

Sorafenib is a tyrosine kinase inhibitor. It is indicated for unresectable hepatocellular carcinoma.

Regorafenib (Stivarga)

Regorafenib is a tyrosine kinase inhibitor. It is indicated for hepatocellular carcinoma in patients who have been previously treated with sorafenib.

Cabozantinib (Cabometyx)

Cabozantinib is an inhibitor of multiple tyrosine kinases, including RET, MET, and VEGFR-2. It is indicated for HCC in patients previously treated with sorafenib.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!